SCA2 may present as levodopa-responsive parkinsonism

Mov Disord. 2003 Apr;18(4):425-9. doi: 10.1002/mds.10375.

Abstract

Some kindreds with familial parkinsonism exhibit genetic anticipation, suggesting possible involvement of trinucleotide repeat expansion. Recent reports have shown trinucleotide repeat expansions in the spinocerebellar ataxia 2 (SCA2) gene in patients with levodopa-responsive parkinsonism. We tested 136 unrelated patients with familial parkinsonism for SCA2 mutations. Two probands had borderline mutations; the rest were normal. (<or=31 repeats is normal, 32-35 is borderline, >or=36 is pathogenic). The expanded allele segregated with neurological signs in one kindred. The absence of borderline mutations in the normal population, and the co-segregation of the expanded allele with neurological signs in one kindred suggest that SCA2 mutations may be responsible for a subset of familial parkinsonism.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Anticipation, Genetic / genetics
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use*
  • Ataxins
  • DNA Mutational Analysis
  • Female
  • Genetic Predisposition to Disease / genetics
  • Genotype
  • Humans
  • Levodopa / adverse effects
  • Levodopa / therapeutic use*
  • Male
  • Middle Aged
  • Nerve Tissue Proteins
  • Neurologic Examination
  • Parkinson Disease / diagnosis
  • Parkinson Disease / drug therapy
  • Parkinson Disease / genetics*
  • Parkinsonian Disorders / diagnosis
  • Parkinsonian Disorders / drug therapy
  • Parkinsonian Disorders / genetics*
  • Pedigree
  • Phenotype
  • Proteins / genetics*
  • Treatment Outcome
  • Trinucleotide Repeats

Substances

  • Antiparkinson Agents
  • Ataxins
  • Nerve Tissue Proteins
  • Proteins
  • Levodopa